drugset

drugset / Trial / NCT05255523

Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer

NCT05255523 ↗

Phase 2 Unknown 60 enrolled Fujian Medical University Union Hospital

NaSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the effect of pyrotinib

Timeline

Start: 2022-02-20
Primary completion: 2023-11-05
Completion: 2024-12-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pyrotinib	Small molecule	400 mg	Oral

Indications